PERFETTO, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.765
EU - Europa 9.742
AS - Asia 7.534
SA - Sud America 841
AF - Africa 222
Continente sconosciuto - Info sul continente non disponibili 200
OC - Oceania 153
Totale 33.457
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.467
RU - Federazione Russa 3.416
SG - Singapore 2.246
CN - Cina 2.041
IT - Italia 1.868
PL - Polonia 1.219
HK - Hong Kong 933
VN - Vietnam 737
IE - Irlanda 709
KR - Corea 703
SE - Svezia 693
BR - Brasile 658
FI - Finlandia 425
DE - Germania 416
FR - Francia 265
UA - Ucraina 260
GB - Regno Unito 203
IN - India 199
CA - Canada 174
BD - Bangladesh 152
AU - Australia 150
JP - Giappone 100
TR - Turchia 93
JO - Giordania 86
NL - Olanda 71
ID - Indonesia 69
AR - Argentina 68
MX - Messico 61
ES - Italia 45
CH - Svizzera 43
EC - Ecuador 36
IQ - Iraq 35
NG - Nigeria 35
ZA - Sudafrica 33
CI - Costa d'Avorio 29
EG - Egitto 27
PK - Pakistan 24
MA - Marocco 22
CL - Cile 21
SC - Seychelles 20
BE - Belgio 19
VE - Venezuela 17
LT - Lituania 15
CO - Colombia 14
SA - Arabia Saudita 14
JM - Giamaica 13
MY - Malesia 12
UZ - Uzbekistan 12
BJ - Benin 11
CR - Costa Rica 10
KE - Kenya 10
TN - Tunisia 9
BO - Bolivia 8
HN - Honduras 8
KZ - Kazakistan 8
AE - Emirati Arabi Uniti 7
AL - Albania 7
AT - Austria 7
DZ - Algeria 7
NP - Nepal 7
PA - Panama 7
PH - Filippine 7
PY - Paraguay 7
RS - Serbia 7
AZ - Azerbaigian 6
PE - Perù 6
PR - Porto Rico 6
PT - Portogallo 6
CZ - Repubblica Ceca 5
DK - Danimarca 5
KG - Kirghizistan 5
LV - Lettonia 5
NI - Nicaragua 5
TH - Thailandia 5
BG - Bulgaria 4
BH - Bahrain 4
BY - Bielorussia 4
IL - Israele 4
SI - Slovenia 4
ET - Etiopia 3
GR - Grecia 3
OM - Oman 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
CG - Congo 2
GE - Georgia 2
HR - Croazia 2
HU - Ungheria 2
IR - Iran 2
KH - Cambogia 2
LB - Libano 2
LU - Lussemburgo 2
MM - Myanmar 2
Totale 33.220
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.149
Singapore 1.618
Ashburn 1.553
Warsaw 1.214
Fairfield 1.005
Hong Kong 755
Chandler 722
Dublin 706
Seoul 697
Hefei 569
San Jose 532
Woodbridge 478
Jacksonville 439
Seattle 403
Milan 387
Houston 382
Cambridge 380
Beijing 362
Wilmington 341
Council Bluffs 265
Los Angeles 254
Helsinki 230
Ho Chi Minh City 224
North Bergen 214
Buffalo 213
The Dalles 185
Lauterbourg 175
Princeton 175
Hanoi 170
Rome 168
Ann Arbor 161
Florence 161
Melbourne 146
Moscow 136
New York 119
Medford 109
Lawrence 107
Boston 105
Munich 105
Altamura 104
Boardman 104
Dallas 94
San Diego 88
Shanghai 83
Mumbai 82
Kent 79
Tokyo 78
São Paulo 67
Naples 61
Jakarta 56
Toronto 47
Frankfurt am Main 45
Izmir 44
London 44
Figino 43
Paris 42
West Jordan 40
Lakewood 39
Redondo Beach 39
Turku 39
Bern 38
Rio de Janeiro 38
Da Nang 37
Turin 37
Chicago 35
Abuja 34
Bologna 34
Orem 34
Palermo 34
Guangzhou 33
Dong Ket 32
Montreal 32
Lappeenranta 31
Chennai 30
Abidjan 29
Phoenix 29
Clifton 28
Norwalk 28
Bengaluru 27
Johannesburg 24
Baghdad 21
Hillsboro 21
Padua 20
Atlanta 19
Falls Church 19
Amsterdam 18
Belo Horizonte 18
Yubileyny 18
Biên Hòa 17
Brooklyn 17
Denver 17
Guayaquil 17
Haiphong 17
Pune 17
Stockholm 17
Brussels 16
Tianjin 16
Adapazarı 15
Miano 15
Pisa 15
Totale 21.426
Salva come PNG Salva come JPEG
Nome #
Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis 372
The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn). 331
Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis. 312
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective 310
Progressive and atypical neurological symptoms in refractory systemic AL amyloidosis 296
Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy 293
Aging related changes of circadian rhythmicity of cytotoxic lymphocyte subpopulations 283
Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon 274
Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis. 242
The Story Behind: Chronome/chrone 240
Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis. 236
Transdisciplinary unifying implications of circadian findings in the 1950s. 235
Different NT-proBNP circulating levels for different types of cardiac amyloidosis 233
Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis 233
Real-world versus trial patients with transthyretin amyloid cardiomyopathy 224
Screening for cardiac amyloidosis in patients with tenosynovial red flags: A collaboration between family medicine and cardiology 221
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 221
Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study. 211
Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis 210
Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure 205
Time related variations in stem cell harvesting of umbilical cord blood 202
Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study 201
Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany 200
Liver dysfunction as predictor of prognosis in patients with amyloidosis: utility of the Model for End-stage Liver disease (MELD) scoring system 199
A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis 198
As we cannot afford to renounce to new generation echocardiography in systemic amyloidosis. 198
The platypnea-orthodeoxia syndrome: an unusual case of dyspnea 197
Depression and cardiac symptoms among AL amyloidosis patients: the mediating role of coping strategies. 195
Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis 195
Exercise Doppler echocardiography identifies preclinic asymptomatic pulmonary hypertension in systemic sclerosis. 192
Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates 192
A new ATTR Phe64Ile mutation with late-onset multiorgan involvement. 191
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience 191
Angiopathy affects circulating endothelin-1 levels in type 2 diabetic patients. 190
Troponins in cardiac amyloidosis: multipurpose markers. 189
Arrhythmic Burden in Cardiac Amyloidosis: What We Know and What We Do Not 187
About-half-weekly (circasemiseptan) component of the endothelin-1 (ET-1) chronome and vascular disease risk. 184
Abrupt onset of refractory heart failure associated with light-chain amyloidosis in hypertrophic cardiomyopathy 184
Genetic and environmental influences on human cord blood leptin concentration. 183
Endothelin-1's chronome indicates diabetic and vascular disease chronorisk. 183
ECG abnormalities, atrial fibrillation and AV blocks in ATTR VS AL amyloidosis: an electrophysiological natural history 183
Red flags for the diagnosis of cardiac amyloidosis: Simple suggestions to raise suspicion and achieve earlier diagnosis 181
Anxiety and depression among amyloid light-chain cardiac amyloidosis patients: The role of life satisfaction. 181
Anxious/Depressive Symptoms Alter the Subjective Perception of Heart Failure Severity in Transthyretin Cardiac Amyloidosis 180
Systemic amyloidosis: a challenge for the rheumatologist. 180
Incidence and characteristics of asymptomatic distal deep vein thrombosis unexpectedly found at admission in an Internal Medicine setting 180
Therapeutic challenges for systemic sclerosis: facts and future targets. 179
Amyloidoses 179
Serial changes in CPET parameters in untreated patients with transthyretin cardiac amyloidosis 178
CIRCADIAN PHASE DIFFERENCE OF LEPTIN IN ANDROID VERSUS GYNOID OBESITY 178
1100 or 30 years after Janeway or Bartter, Healthwatch helps avoid 'flying blind'. 178
Age-dependent association of exposure to television screen with children's urinary melatonin excretion? 178
Prevalence of transthyretin-related amyloidosis in Tuscany: Data from the regional population-based registry 176
Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy 176
Amyloidosis, inflammation, and oxidative stress in the heart of an alkaptonuric patient 176
Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study 175
Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial. 174
CHRONOASTROBIOLOGY: PROPOSAL, NINE CONFERENCES, HELIOGEOMAGNETICS, TRANSYEARS, NEAR-WEEKS, NEAR-DECADES, PHYLOGENETIC AND ONTOGENETIC MEMORIES. 174
Treatment of cardiac transthyretin amyloidosis: an update 174
Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype 174
Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients 173
Anxiety and depression among AL amyloidosis patients: The role of cardiac symptoms 172
Therapeutic challenges for systemic sclerosis: facts and future targets. 172
Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 172
Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis. 171
Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy 170
Measurement of myocardial amyloid deposition in systemic amyloidosis: Insights from cardiovascular magnetic resonance imaging 169
Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems 169
Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis 169
Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy 168
Chronomics, neuroendocrine feedsidewards and the recording and consulting of nowcasts--forecasts of geomagnetics. 168
Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis 167
Cardiac amyloidosis in patient undergoing TAVR, why we need to think about it 167
Endothelin-1 and Paget's bone disease: is there a link? 167
ATTRv amyloidosis Italian Registry: clinical and epidemiological data 167
Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities? 167
The Role of T2 Mapping in Cardiac Amyloidosis 166
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 166
Evidence for bone mass and body fat distribution relationship in postmenopausal obese women. 166
Investigation on the high recurrence of the ATTRv-causing transthyretin variant Val142Ile in central Italy 165
Chronome assessment of circulating melatonin in humans. 165
Rotational mechanics of the left ventricle in AL amyloidosis 164
Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis 163
Influence of non-insulin-dependent diabetes mellitus on plasma endothelin-1 levels in patients with advanced atherosclerosis. 162
Caregiver’s psychological well-being and quality of relationship with cardiac amyloidosis patients 161
Transthyretin Cardiac Amyloidosis: A Cardio-Orthopedic Disease 161
SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series 161
Daytime circulating melatonin levels in smokers. 161
Colestasi intraepatica in corso di amiloidosi sistemica AL senza evidenza istologica di un coinvolgimento epatico: un caso di epatopatia tossica o una mancata diagnosi di amiloidosi epatica? 160
Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: a Multicenter Network Study 158
Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis 158
Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value 157
Serum beta-endorphin increase after intravenous histamine treatment of chronic daily headache. 157
Baseline ECG features and arrhythmic profile in transthyretin versus light chain cardiac amyloidosis 157
Is Hereditary Transthyretin Amyloidosis the Third Leading Cause of Monogenic Chronic Kidney Disease, Only Behind ADPKD and Alport Disease? 155
POINT AND INTERVAL ESTIMATIONS OF CIRCADIAN MELATONIN ECPHASIA IN SMITH-MAGENIS SINDROME 154
Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarciodosis 154
Wild-Type ATTR Amyloidosis 153
The Story Behind: Pineal mythology and chronorisk. The Swan Song of Brunetto TARQUINI. 153
Diagnosis of secondary amyloidosis in alkaptonuria 153
Totale 19.125
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.786
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.786
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.068 0 98 40 55 26 62 34 73 60 101 214 305
2022/20233.023 274 406 130 224 237 593 439 187 332 32 97 72
2023/20241.349 55 145 192 57 90 144 55 310 25 105 100 71
2024/20259.414 326 913 575 1.513 2.744 1.213 189 440 467 214 403 417
2025/202611.334 1.244 1.599 1.119 884 1.173 465 1.424 514 688 641 410 1.173
2026/20271.088 511 577 0 0 0 0 0 0 0 0 0 0
Totale 33.457